Brokerages Anticipate Rexahn Pharmaceuticals, Inc. (RNN) to Post ($0.02) Earnings Per Share
Rexahn Pharmaceuticals, Inc. (NYSE:RNN) has earned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating.
Brokers have set a 12 month consensus price target of $3.00 for the company and are predicting that the company will post ($0.02) EPS for the current quarter, according to Zacks. Zacks has also assigned Rexahn Pharmaceuticals an industry rank of 105 out of 265 based on the ratings given to its competitors.
Several equities analysts have recently commented on RNN shares. FBR & Co restated an “outperform” rating and issued a $3.00 price objective on shares of Rexahn Pharmaceuticals in a research report on Wednesday, October 5th. Zacks Investment Research downgraded Rexahn Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, October 12th.
Shares of Rexahn Pharmaceuticals (NYSE:RNN) opened at 0.1705 on Friday. The company’s 50-day moving average price is $0.22 and its 200 day moving average price is $0.27. Rexahn Pharmaceuticals has a one year low of $0.16 and a one year high of $0.52. The stock’s market capitalization is $36.37 million.
Rexahn Pharmaceuticals (NYSE:RNN) last released its earnings results on Monday, August 8th. The company reported ($0.01) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.02) by $0.01. Analysts anticipate that Rexahn Pharmaceuticals will post ($0.07) EPS for the current year.
A hedge fund recently raised its stake in Rexahn Pharmaceuticals stock. Vanguard Group Inc. increased its position in Rexahn Pharmaceuticals, Inc. (NYSE:RNN) by 1.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,904,097 shares of the company’s stock after buying an additional 49,761 shares during the period. Vanguard Group Inc. owned approximately 2.30% of Rexahn Pharmaceuticals worth $1,232,000 at the end of the most recent reporting period.
About Rexahn Pharmaceuticals
Rexahn Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company’s clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Rexahn Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.